The atopic dermatitis space is one of the hottest areas in immune disease at present and Sanofi, already a key player with the blockbuster Dupixent, and Amgen, Inc. (and partner Kyowa Kirin Co., Ltd.) have presented promising data on their respective investigational therapies which both target the OX40 pathway.
Sanofi And Amgen Make The Case For OX40 Drugs In Atopic Dermatitis
Two Therapies That Could Rival Dupixent
As the European Academy of Dermatology and Venerology congress closed its doors, two OX40 atopic dermatitis drugs from Sanofi and Amgen/Kyowa Kirin caught the eye.
More from Immunological
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.